Related Experiment Video

Updated: May 26, 2026

Rodent Inferior Vena Cava Venoplasty Balloon Model
05:44

Rodent Inferior Vena Cava Venoplasty Balloon Model

Published on: May 24, 2024

Statins for primary prevention of venous thromboembolism

Lun Li1, Tiantian Sun, Peizhen Zhang

  • 1Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, No. 199, Donggang West Road, Lanzhou City, Gansu, China, 730000.

The Cochrane Database of Systematic Reviews
|December 14, 2011
PubMed

Insights

This study found that rosuvastatin may reduce the incidence of venous thromboembolism (VTE) and deep vein thrombosis (DVT). However, more randomized controlled trials are needed to confirm the efficacy of statins for VTE prevention.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Clinical Trials

Background:

  • Venous thromboembolism (VTE) is a prevalent clinical condition.
  • The role of statins in primary VTE prevention is not well-established.

Purpose of the Study:

  • To evaluate the efficacy of statins for the primary prevention of VTE.
  • To synthesize evidence from randomized controlled trials (RCTs) on statin use for VTE prevention.

Main Methods:

  • A comprehensive literature search was conducted across multiple databases (MEDLINE, EMBASE, Cochrane CENTRAL, etc.) up to March 2011.
  • Included one RCT assessing rosuvastatin for VTE prevention, with data extraction and risk of bias assessment performed independently by two authors.

Main Results:

  • Rosuvastatin significantly reduced the incidence of VTE (OR 0.57) and deep vein thrombosis (DVT) (OR 0.45).
  • Rosuvastatin also decreased the risk of myocardial infarction (MI) and stroke but did not significantly impact pulmonary embolism (PE) or death after VTE.
  • No significant reduction in serious adverse events was observed with rosuvastatin.

Conclusions:

  • Limited evidence from a single RCT suggests rosuvastatin may reduce VTE incidence.
  • Further large-scale randomized controlled trials are necessary to definitively establish the efficacy of statins, including rosuvastatin, in VTE prevention.
Abstract

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...